Deliver Your News to the World

Transcriptogen LTD raises key early stage investment from Deepbridge Capital

TSG1301 binding in the minor groove of DNA
TSG1301 binding in the minor groove of DNA

Transcriptogen Ltd is a drug Discovery Company pioneering effective treatment for Pancreatic Cancer with minimal side effects using an approach never used before.  The research has been spun out of Kings College and the company is based in Bath and London. Pancreatic Cancer treatment is an unmet need: 8,500 die in the UK and the chance of surviving 5 years is 5%.

Dr Savvas Neophytou, Partner and Head of Life Sciences at Deepbridge Capital, commented:
“We are delighted to be providing funding and support to Transcriptogen.  From an investment perspective, cancer treatments are not only satisfying a growing international need but for many also evoke an emotional connection.   The proposition and team at Transcriptogen represents an appealing investment opportunity.”
Richard Turner, CEO of Transcriptogen, commented:
We are pleased to have secured this funding via Deepbridge. It builds on funding of over 2.5m from research organizations to get us to where we are. Deepbridge join Astra Zeneca and Kings College as our other major shareholders. The next step for Transcriptogen is to take our lead molecule into the clinic and begin human trials.” 

- END -
For further information please contact:
Richard J Turner: Telephone 07879 423828.
Paragon House, Lyncombe Vale Road, Bath, BA24LS
Notes for Editors
Transcriptogen’s drugs inhibit the transcription factors that control the function of all genes. These transcription factors are often found to excess in cancer cells. Core intellectual property and know how is based on five years of research within University College London, funded by organizations including Cancer Research UK and the Commonwealth Fund.

This research has revealed that control of the transcription factors allows the possibility of successfully treating cancer with a dramatic reduction in side effects.  The agents patented by Transcriptogen Limited - which selectively bind to the human genome to control transcriptions factors - are active at very low concentrations. They therefore have lower toxicity than conventional cancer chemotherapies.

Transcriptogen Limited has a portfolio of molecules derived from its lead generation platform technology. The initial focus is on pancreatic and breast cancer but the pipeline of drugs to be developed by Transcriptogen Limited are potentially effective in treating all forms of cancer.


( Press Release Image: )


 Drug Discovery
 Transcription Factors
 Novel Mechanism
 Pancreatic Cancer
 Breast Cancer

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.